The next breakthrough drug might already be sitting on a pharmacy shelf. This episode reveals how AI and omics data are decoding old drugs' hidden potential and rewriting the future of medicine.
AI is transforming drug discovery by matching disease patterns to existing medications using multi-omics data. This episode of Builder's Creed explores how artificial intelligence and biological data are making treatment discovery faster, more personalized, and more precise.
Welcome to Builder's Creed, the show for the doers, the closers, and the operators building real businesses from the ground up.
Every week we dive into the topics that matter for leaders in the trades, from how to keep your body right to how to grow your business, to how to manage your sales org, and everything in between.
This isn't theory, it's the playbook straight from the people living it.
If you're building something of your own, you're in the right place.
Let's get into it.
What if the next breakthrough medicine is not sitting in a secret lab?
What if it is not locked behind 10 more years of research, billions of dollars, and another endless approval race?
What if the next medical breakthrough is already here?
But we missed it.
For decades, medicine has looked at drugs like single-purpose tools.
This drug is for blood pressure.
This drug is for diabetes.
This drug is for cancer.
But biology does not work like a filing cabinet.
The body is a network.
And now AI is starting to read that network.
It is scanning DNA, proteins, metabolites, gene expression, immune signals, and epigenetic shifts.
And it is asking a new question.
What if an old drug has a new job?
That is the frontier we are talking about today.
AI-powered drug repurposing using Omics data.
And if this works at scale, it could change how we discover treatments, how we prevent disease, how we think about longevity, and how we build the next healthcare operating system.
What does it mean to be a builder?
It is the mindset to create something from nothing and to bet on yourself when no one else does.
I am the AI Avatar representing Justin Brock, founder and CEO of Subcontractor Hub, the operating system for builders.
He has adopted all aspects of AI, and I help him get you the information you need while things are moving forward so quickly.
This is the Builder's Creed, where we explore the mindset of the people who create, risk, and rebuild, because building something real is the most powerful act of rebellion there is.
Today's episode is about the builders rebuilding medicine from the inside out.
People looking at a slow, expensive, failure-heavy drug discovery system and asking, what are we missing?
The old model has produced miracles, but it also leaves too many people behind.
Rare disease patients, chronic disease patients, and aging populations.
So the real question is not, can AI replace medicine?
The real question is, can AI help medicine see what it has been missing?
In drug repurposing, the answer may be yes.
Drug repurposing means finding new uses for drugs that already exist.
In the past, this often happened by accident.
A drug was created for one condition, doctors noticed another effect, and that side effect became a new clue.
Now AI is making that search intentional.
It can compare the molecular pattern of a disease with the molecular pattern of a drug.
If a disease pushes the body in one harmful direction, AI can ask, can this existing drug push the body back toward balance?
That is the core idea.
Old drugs, new biological maps, a eye-powered pattern matching.
And this is becoming possible because we are entering the age of omics.
Omics means looking at entire layers of biology at scale, not one gene or protein or lab marker, a whole layer.
And each layer tells a different part of the story.
Genomics tells you what could happen.
Transcriptomics tells you what is being expressed.
Proteomics tells you what is being built.
Metabolomics tells you what is happening chemically.
Epigenomics tells you how the environment, aging, lifestyle, and disease may be changing the way the system behaves.
One layer is useful, but one layer is not enough because disease is rarely one switch.
It is usually a network failure.
Cancer is not just abnormal cell growth.
It can involve immune escape, genetic mutations, metabolic shifts, inflammation, and changes in the tumor environment.
Alzheimer's is not just memory loss.
It can involve protein buildup, vascular changes, immune dysfunction, inflammation, and metabolic stress.
Heart disease is not just clogged arteries.
It can involve inflammation, metabolism, blood pressure, genetics, kidney function, and cellular energy.
This is why multi-omics matters.
It gives us a systems view, and builders understand systems.
If a building has cracks, you do not just paint the wall, you know, you check the foundation, load, water damage, and more.
That is what multi-omics is trying to do for the human body.
It is looking under the surface.
And AI is the engine that makes that data useful.
Here is the problem.
Omics data is massive.
We are talking about billions of data points.
No human can manually connect all of that, but AI can search the space and look for correlations.
It can compare drug effects against disease patterns at a scale humans could never handle manually.
This is where the Arab News article becomes important.
The article talks about Saudi Arabia's push to integrate artificial intelligence with omics-based diagnostics as part of a larger move toward personalized preventive healthcare.
One of the companies highlighted is Rewind, a Saudi-based company using AI and Omics technologies to move healthcare away from a generalized reactive model and toward a more personalized, proactive one.
That phrase matters, personalized and proactive, because most healthcare is still generalized and reactive.
AI plus Omics turns medicine from a category system into a pattern system.
Instead of asking only, what disease does this person have?
The new system asks, what is happening inside this person?
What pathways are disrupted?
That is the future.
Now let's talk about why repurposing matters so much.
The traditional drug development pipeline is brutal.
Discovery, preclinical research, clinical trials, regulatory review, post-market monitoring.
Every step matters.
Every step exists for a reason.
We need safety, evidence, and real clinical validation.
But the process is long, expensive, and failure heavy.
A brand new drug may take many years to move from idea to patient.
Drug repurposing is powerful because it changes the starting point.
Instead of starting with a brand new molecule, you start with something that already has human safety data, manufacturing history, dosing knowledge, and clinical familiarity.
That does not mean it is automatically safe for a new use.
It does not mean you skip validation.
It does not mean patients should experiment on themselves.
Absolutely not.
But it can reduce uncertainty.
It can speed up hypothesis testing, make neglected diseases more viable, and give researchers a smarter path into complex conditions.
And when AI is used properly, it can help find candidates that humans might never have considered.
That is the value proposition.
Faster search, better matching, lower waste, more shots on goal.
Here is a simple framework for how AI-powered drug repurposing works.
Four layers.
Layer one, read the body.
Layer two, define the disease signature.
Layer three, match the drug signature.
Layer four, validate in reality.
Let's break that down.
Layer one, read the body.
This is where omics comes in.
Genomics, proteomics, metabolomics, epigenomics, transcriptomics, clinical data, imaging, wearables, lab history.
The goal is to understand the system.
Layer two, define the disease signature, treat it as a biological pattern.
This is where early detection becomes possible.
The Arab News article makes this point clearly.
Ohmics-based diagnostics can help detect diseases at their earliest molecular stages, often before clinical symptoms appear.
That is a major shift.
Because once symptoms show up, the fire may already be spreading.
Layer three, match the drug signature.
Every drug leaves a footprint.
AI can compare the disease footprint with drug footprints.
If a drug appears to reverse part of the disease signature, it becomes a candidate.
Layer four, validate in reality.
This is the layer people like to skip, but builders cannot skip it.
The model is not the medicine.
The prediction is not the outcome.
The AI generated match must be tested in cells, in animals where appropriate, in carefully designed human trials, with real patience, safety monitoring, dosage studies, ethical oversight, and clinicians involved.
This is where the field will either mature or collapse into noise.
AI can generate leads, but biology gets the final vote, and biology is undefeated at humbling people.
Now we need to talk about what can break this.
In AI-powered healthcare, there are three big ones data infrastructure, clinical literacy, ethical governance.
First, data infrastructure.
Healthcare data is fragmented.
Hospitals have one system, labs have another, data formats do not match, quality varies, labels are messy, and AI needs clean, connected, meaningful data to work well.
If the data layer is broken, the AI layer becomes fragile.
Bad, disconnected data creates bad predictions.
Second, clinical literacy.
Doctors and healthcare teams need to understand how to use AI-generated insights, not blindly trust them, not dismiss them, interpret them, challenge them, translate them into care.
The Arab News article points out that healthcare providers need targeted training to interpret AI insights and turn them into patient-centered action.
That is critical because AI and medicine cannot just be technically impressive.
It has to fit into real clinical workflows.
Third, ethical governance.
This might be the most important one because biological data is intimate.
Your genome disease risk or aging profile is not just data.
This is deeply personal information.
So who owns it, controls it, or access it?
Can governments misuse it?
Can companies train models on it without meaningful consent?
How do we protect privacy while still enabling research?
These are not side issues.
These are the foundation.
If the public does not trust the system, the system will fail.
And it should fail if it cannot protect people.
Builders in healthcare have to move fast enough to matter, but carefully enough to be trusted.
That is the standard.
This is not just a healthcare story.
It is a system story.
In medicine, AI, and Omics matter because they connect scattered data and turn it into better decisions.
The same problem exists in home services.
Sales, financing, project management, documents, compliance, and customer communication often live in separate places.
That fragmentation creates delays, missed details, and reactive decisions.
Subcontractor Hub solves that by bringing the core parts of a home service business into one AI-powered operating system for solar, roofing, and HVAC contractors.
The lesson is simple.
When data is disconnected, builders react.
When systems are connected, builders move faster, see earlier, and operate with more control.
Over the next decade, drug discovery may become less random and more precise.
Old drugs will be tested against new biological maps.
Rare diseases may get more chances.
Chronic disease care may become more personalized.
And longevity may move from vague wellness claims to measurable molecular science.
But we have to stay grounded.
AI will not cure everything.
Omics will not explain everything.
And not every predicted drug match will work.
The real future belongs to builders who can combine data, biology, validation, ethics, and trust.
Because the question is not just what can AI find.
The real question is what system must exist for AI to actually help people?
So let's come back to the opening idea.
What if the next breakthrough drug already exists?
And what if we simply never had the tools to see its full potential?
AI and Omics may change that.
They allow us to read the body at a deeper level and compare that pattern against thousands of existing drugs.
And they allow us to ask one of the most powerful builder questions.
What else can this do?
That question is bigger than medicine.
It is the question behind every transformation.
That is why this matters, because progress is not always about replacing the old.
Sometimes progress is about finally understanding it.
I'm Justin Brock's AI Avatar, and this is Builder's Creed.
If this episode made you think differently about AI, medicine, longevity, or systems, send it to one person who needs to hear it.
Because the next frontier is not just about building more, it is about building smarter.
And sometimes the most powerful act of rebellion is looking at an old tool and realizing it still has work left to do.
That's a wrap on this one.
To everyone in the Builders Creed community, thank you for being here, for showing up, and for building alongside us.
None of this works without you.
If this episode hit home, do me a favor, hit that like button, subscribe so you never miss an episode, and share it with someone who needs to hear it.
Until next time, keep building.
EP-16Some AI data centers now draw more power than entire cities, triggering historic events. This episode explores what’s really powering the AI revolution, and why builders, not coders, are the ones determining how fast it actually arrives.
EP-15Exercise may be doing far more than changing what you see in the mirror. Research into trained older muscle suggests long-term physical activity may help preserve parts of the molecular machinery tied to energy, adaptation and resilience.
EP-14Biology does not operate one gene or pathway at a time. AI is helping researchers model the interactions between those pieces, creating a new way to explore how cells behave, respond and change before every question reaches the lab.
Resources
